P. Harrigan

发表

Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.

P. Harrigan, K. Hertogs, W. Verbiest, 1999, AIDS.

Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors.

T. Silander, D. Katzenstein, Y. Moreau, 2007, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Bayesian network analyses of resistance pathways against efavirenz and nevirapine

D. Katzenstein, R. Shafer, M. Soares, 2008, AIDS.

Prediction of response to antiretroviral therapy by human experts and by the EuResist data‐driven expert system (the EVE study)

Thomas Lengauer, A. Wensing, R. Kaiser, 2010, HIV medicine.

Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation.

Steven M. Shechter, M. Roberts, P. Harrigan, 2006, The Journal of antimicrobial chemotherapy.

The Long-Term Outcomes of an Antibiotic Control Program with and without Education

P. Harrigan, Z. Brumme, C. Chui, 2007 .

Predicting HIV Coreceptor Usage on the Basis of Genetic and Clinical Covariates

Andrew J. Low, Thomas Lengauer, F. S. Domingues, 2007, Antiviral therapy.

World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing

P. Harrigan, W. Verbiest, B. Larder, 2001, AIDS.

Phylogenetic analysis of population-based and deep sequencing data to identify coevolving sites in the nef gene of HIV-1.

Sergei L. Kosakovsky Pond, J. Mullins, D. Richman, 2010, Molecular biology and evolution.

Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing

John Archer, David L Robertson, B. Taillon, 2009, AIDS.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

Jack T Stapleton, Stuart Haber, David Heckerman, 2010, Science.

Mapping the Shapes of Phylogenetic Trees from Human and Zoonotic RNA Viruses

Art F. Y. Poon, Richard H. Liang, Rosemary M. McCloskey, 2013, PloS one.

Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study

Art F. Y. Poon, Mel Krajden, Jason Wong, 2016, The lancet. HIV.

Factors Influencing the Sensitivity and Specificity of Conventional Sequencing in Human Immunodeficiency Virus Type 1 Tropism Testing

P. Harrigan, D. Knapp, A. Poon, 2012, Journal of Clinical Microbiology.

Genotypic tropism testing: evidence-based or leap of faith?

P. Harrigan, A. Geretti, 2011, AIDS.

Mutations in Gp41 are Correlated with Coreceptor Tropism but Do Not Improve Prediction Methods Substantially

Thomas Lengauer, P. Harrigan, H. Valdez, 2011, Antiviral therapy.

CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals.

Andrew J. Low, P. Harrigan, R. Hogg, 2008, AIDS research and human retroviruses.

The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic

Evan Wood, Thomas Kerr, Adrian R Levy, 2006, The Lancet.

Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism.

Richard H. Liang, Rosemary M. McCloskey, P. Harrigan, 2015, The Journal of infectious diseases.

Uncommon Pathways of Immune Escape Attenuate HIV-1 Integrase Replication Capacity

D. Heckerman, E. Rosenberg, H. Jessen, 2012, Journal of Virology.

Comparison of population and 454 "deep" sequence analysis for HIV type 1 tropism versus the original trofile assay in non-B subtypes.

P. Harrigan, A. Poon, H. Valdez, 2013, AIDS research and human retroviruses.

Population-Based Sequencing of the V3-loop Can Predict the Virological Response to Maraviroc in Treatment-Naive Patients of the MERIT Trial

P. Harrigan, H. Valdez, A. Thielen, 2012, Journal of acquired immune deficiency syndromes.

Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.

M. Jensen, P. Harrigan, D. Knapp, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Correlation of the Virological Response to Short-Term Maraviroc Monotherapy with Standard and Deep-Sequencing-Based Genotypic Tropism Prediction Methods

P. Harrigan, A. Poon, E. Ruiz-Mateos, 2011, Antimicrobial Agents and Chemotherapy.

Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies

P. Harrigan, H. Valdez, A. Thielen, 2010, AIDS.

Genotypic determination of HIV-1 tropism in the clinical setting

P. Harrigan, A. Thielen, L. C. Swenson, 2010 .

Improved Detection of CXCR4-Using HIV by V3 Genotyping: Application of Population-Based and “Deep” Sequencing to Plasma RNA and Proviral DNA

Andrew J. Low, M. Jensen, P. Harrigan, 2010, Journal of acquired immune deficiency syndromes.

Genotypic inference of HIV-1 tropism using population-based sequencing of V3.

P. Harrigan, L. C. Swenson, R. McGovern, 2010, Journal of visualized experiments : JoVE.

Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure.

P. Harrigan, K. Hertogs, R. Pauwels, 1998, The Journal of infectious diseases.

Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group

R. Schooley, P. Harrigan, B. Larder, 1996, Journal of virology.

HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure

P. Harrigan, J. Montaner, Jonathan Z. Li, 2014, AIDS.

The Impact of Adherence on CD4 Cell Count Responses Among HIV-Infected Patients

P. Harrigan, B. Yip, R. Hogg, 2004, Journal of acquired immune deficiency syndromes.

Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 109 cells/L

Julio S. G. Montaner, P. Harrigan, B. Yip, 2003, Annals of Internal Medicine.

Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada

Brandon D. L. Marshall, O. Pybus, P. Harrigan, 2014, Hepatology.

Genotypic and Functional Impact of HIV-1 Adaptation to Its Host Population during the North American Epidemic

M. Carrington, B. Walker, J. Fuchs, 2014, PLoS genetics.

No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy

P. Harrigan, R. Hogg, J. Montaner, 2002, AIDS.

Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic

M. Carrington, B. Walker, J. Fuchs, 2015, Journal of Virology.

Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis : pragmatic multicentre randomised controlled non-inferiority trial ( PLUTO study )

P. Harrigan, R. Hogg, J. Montaner, 2009 .

HIV coreceptor phenotyping in the clinical setting.

Andrew J. Low, P. Harrigan, L. C. Swenson, 2008, AIDS reviews.

Improved Genotypic Prediction of HIV-1 Coreceptor Usage by Incorporating V2 Loop Sequence Variation

Thomas Lengauer, Rolf Kaiser, Andrew Moores, 2008 .

Improved Detection of X4 Virus by V3 Genotyping: Application to Plasma RNA and Proviral DNA

Andrew J. Low, M. Jensen, P. Harrigan, 2008 .

Trofile HIV co-receptor usage assay.

Andrew J. Low, P. Harrigan, Andrew J Low, 2009, Expert opinion on medical diagnostics.

Phylogenetic approach to recover integration dates of latent HIV sequences within-host

Bradley R. Jones, P. Harrigan, J. Joy, 2018, Proceedings of the National Academy of Sciences.

Application and Validation of Case-Finding Algorithms for Identifying Individuals with Human Immunodeficiency Virus from Administrative Data in British Columbia, Canada

P. Harrigan, B. Yip, R. Hogg, 2013, PloS one.

Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.

P. Harrigan, J. Montaner, J. Raboud, 1999, Journal of acquired immune deficiency syndromes.

An assessment of the relationship between the World Health Organization HIV drug resistance early warning indicators and HIV drug resistance acquisition

P. Harrigan, P. Sereda, J. Montaner, 2017, HIV medicine.

Expanded HAART Coverage is Associated with Decreased Population-level HIV-1-RNA and Annual New HIV Diagnoses in British Columbia, Canada

Julio S. G. Montaner, P. Harrigan, B. Yip, 2011 .

Absolute Leukocyte Telomere Length in HIV-Infected and Uninfected Individuals: Evidence of Accelerated Cell Senescence in HIV-Associated Chronic Obstructive Pulmonary Disease

J. Leipsic, P. Harrigan, J. Montaner, 2015, PloS one.

Impact of Pre-adapted HIV Transmission

Charles E. DeZiel, Todd M. Allen, D. Heckerman, 2016, Nature Medicine.

Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America

Sally S Bebawy, Richard D Moore, J. Goedert, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A molecular phylogenetics-based approach for identifying recent hepatitis C virus transmission events.

Andrea D. Olmstead, P. Harrigan, J. Montaner, 2015, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Novel HLA class I associations with HIV-1 control in a unique genetically admixed population

P. Harrigan, S. Ávila-Ríos, G. Reyes-Terán, 2018, Scientific Reports.

Rapid Decrease in Peripheral Blood Mononucleated Cell Telomere Length After HIV Seroconversion, but Not HCV Seroconversion

P. Harrigan, M. Muñoz-Fernández, H. Côté, 2017, Journal of acquired immune deficiency syndromes.

Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) cohort.

P. Harrigan, B. Yip, R. Hogg, 2015, International journal of epidemiology.

Limited Evolution of Inferred HIV-1 Tropism while Viremia Is Undetectable during Standard HAART Therapy

P. Harrigan, B. Yip, D. Knapp, 2014, PloS one.

Comparative Performances of HIV-1 RNA Load Assays at Low Viral Load Levels: Results of an International Collaboration

M. Poljak, A. Wensing, P. Harrigan, 2013, Journal of Clinical Microbiology.

When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients.

P. Harrigan, R. Hogg, J. Montaner, 2005, The Lancet. Infectious diseases.

Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring.

P. Harrigan, M. Johnson, R. van Leeuwen, 1998, The Journal of infectious diseases.

Human Immunodeficiency Virus Phylogenetics in the United States-and Elsewhere.

P. Harrigan, H. Lapointe, 2020, The Journal of infectious diseases.

Increasing prevalence of K65K and K66K in HIV-1 subtype B reverse transcriptase

P. Harrigan, N. Sluis-Cremer, C. Brumme, 2016, AIDS.

Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada.

Andrea D. Olmstead, O. Pybus, P. Harrigan, 2016, Journal of hepatology.

Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts ≥ 200 cells/μl

P. Harrigan, B. Yip, R. Hogg, 2006, AIDS.

Epidemiology of CXCR 4-Using HIV-1 in a Large Population of Antiretroviral-Naive Individuals

P. Harrigan, R. Hogg, J. Montaner, 2005 .

A historical review of HIV prevention and care initiatives in British Columbia, Canada: 1996-2015

P. Harrigan, J. Montaner, T. Kerr, 2017, Journal of the International AIDS Society.

Non-R5-tropic HIV-1 in subtype A1 and D infections were associated with lower pretherapy CD4+ cell count but not with PI/(N)NRTI therapy outcomes in Mbarara, Uganda

Jeffrey N. Martin, P. Harrigan, A. R. Mocello, 2016, AIDS.

Early Selection in Gag by Protective HLA Alleles Contributes to Reduced HIV-1 Replication Capacity That May Be Largely Compensated for in Chronic Infection

Todd M. Allen, D. Heckerman, E. Rosenberg, 2010, Journal of Virology.

Differential Escape Patterns within the Dominant HLA-B*57:03-Restricted HIV Gag Epitope Reflect Distinct Clade-Specific Functional Constraints

B. Walker, R. Haubrich, M. John, 2014, Journal of Virology.

Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa?

Jeffrey N. Martin, P. Harrigan, M. Siedner, 2017, Journal of acquired immune deficiency syndromes.

Correction: Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1

D. Heckerman, B. Walker, C. Kadie, 2007, PLoS pathogens.

Viral adaptation to immune selection pressure by HLA class I–restricted CTL responses targeting epitopes in HIV frameshift sequences

D. Heckerman, P. Harrigan, C. Brander, 2010, The Journal of experimental medicine.

Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase Inhibitors

P. Harrigan, M. Robbins, P. Cheung, 2018, The Journal of infectious diseases.

The impact of clinical, demographic and risk factors on rates of HIV transmission: a population-based phylogenetic analysis in British Columbia, Canada.

P. Harrigan, R. Hogg, J. Montaner, 2015, The Journal of infectious diseases.

Correlates of Protective Cellular Immunity Revealed by Analysis of Population-Level Immune Escape Pathways in HIV-1

David Heckerman, Jennifer Listgarten, Nico Pfeifer, 2012, Journal of Virology.

Immune Screening Identifies Novel T Cell Targets Encoded by Antisense Reading Frames of HIV-1

D. Heckerman, P. Harrigan, C. Brander, 2015, Journal of Virology.

HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins

David W. Haas, David Heckerman, Carl M. Kadie, 2009, PloS one.

A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control

David Heckerman, Jacques Fellay, Christoph Lippert, 2013, eLife.

Association of the CCR5Δ32 Mutation with Clinical Response and >5-year Survival following Initiation of First Triple Antiretroviral Regimen

P. Harrigan, R. Hogg, J. Montaner, 2005, Antiviral Therapy.

CCR5Δ32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response

P. Harrigan, R. Hogg, J. Montaner, 2001, AIDS.

A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression.

Julio S. G. Montaner, P. Harrigan, B. Yip, 2006, The Journal of infectious diseases.

Longitudinal study of surrogate aging measures during human immunodeficiency virus seroconversion

Alexander M. Morin, S. Horvath, P. Harrigan, 2017, Aging.

Signiﬁcance and Clinical Management of Persistent Low-Level Viremia and Very-Low-Level Viremia in HIV-1-Infected Patients

P. Harrigan, Patrick A Ryscavage, B. Taiwo, 2014 .

Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study.

P. Harrigan, J. Montaner, E. Wood, 2017, The lancet. HIV.

CHAPTER 46 – Antiretroviral Therapy of Drug-resistant HIV

P. Harrigan, J. Montaner, M. Harris, 2008 .

Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.

P. Harrigan, A. Poon, H. Valdez, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Is antiretroviral therapy modifying the HIV epidemic? – Authors' reply

P. Harrigan, J. Montaner, E. Wood, 2010, The Lancet.

Superior virological response to boosted protease inhibitor‐based highly active antiretroviral therapy in an observational treatment programme

P. Harrigan, B. Yip, E. Wood, 2007, HIV medicine.

Exploring Mitochondrial Nephrotoxicity as a Potential Mechanism of Kidney Dysfunction among HIV-Infected Patients on Highly Active Antiretroviral Therapy

P. Harrigan, B. Yip, R. Hogg, 2006, Antiviral Therapy.

Improving the clinical relevance of a mouse pregnancy model of antiretroviral toxicity; a pharmacokinetic dosing‐optimization study of current HIV antiretroviral regimens

P. Harrigan, L. Serghides, Smriti Kala, 2018, Antiviral research.

Hospitalization Rates and Causes among Persons with HIV in the US and Canada, 2005-2015.

Richard D Moore, Jennifer S. Lee, Jeffrey N. Martin, 2020, The Journal of infectious diseases.

P080: Characterizing hepatitis C virus transmission dynamics using molecular phylogenetic‐based methods

P. Harrigan, J. Joy, Y. Khudyakov, 2015 .

Replicationd Patients with Ongoing HIV-1 Dynamics and Coreceptor Usage in

V. Calvez, P. Harrigan, H. Fleury, 2014 .

Genotypic Analysis of the V3 Region of HIV from Virologic Nonresponders to Maraviroc-Containing Regimens Reveals Distinct Patterns of Failure

P. Harrigan, H. Valdez, C. Chui, 2013, Antimicrobial Agents and Chemotherapy.

Replication Maraviroc-Treated Patients with Ongoing HIV-1 Dynamics and Coreceptor Usage in

V. Calvez, P. Harrigan, H. Fleury, 2013 .

HIV-1 Dynamics and Coreceptor Usage in Maraviroc-Treated Patients with Ongoing Replication

V. Calvez, P. Harrigan, B. Masquelier, 2012, Antimicrobial Agents and Chemotherapy.

Reply to Abbate et al

P. Harrigan, L. C. Swenson, 2011 .

Perinatal exposure to antiretroviral therapy is associated with increased blood mitochondrial DNA levels and decreased mitochondrial gene expression in infants.

P. Harrigan, J. Raboud, D. Money, 2008, The Journal of infectious diseases.

Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.

P. Harrigan, J. Montaner, S. Guillemi, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Exploring Mitochondrial Nephrotoxicity as a Potential Mechanism of Kidney Dysfunction among HIV-Infected Patients on Highly Active Antiretroviral Therapy

P. Harrigan, B. Yip, R. Hogg, 2006, Antiviral therapy.

Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Rebound of plasma HIV viral load following prolonged suppression with combination therapy.

P. Harrigan, M. Harris, J. Montaner, 1998, AIDS.

Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.

C. Charpentier, P. Harrigan, C. Katlama, 2015, The Journal of antimicrobial chemotherapy.

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.

S D Kemp, P. Harrigan, B. Larder, 1995, Science.

Expansion of HAART Coverage Is Associated with Sustained Decreases in HIV/AIDS Morbidity, Mortality and HIV Transmission: The “HIV Treatment as Prevention” Experience in a Canadian Setting

P. Harrigan, B. Yip, R. Hogg, 2014, PloS one.

Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.

A. Levy, P. Harrigan, R. Hogg, 2008, The Journal of infectious diseases.

The direct costs of HIV/AIDS care.

A. Levy, P. Harrigan, R. Hogg, 2006, Lancet. Infectious Diseases (Print).

Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?

Evan Wood, P. Harrigan, B. Yip, 2003, AIDS.

A systematic review of the genetic mechanisms of dolutegravir resistance

Philip L. Tzou, J. Ioannidis, R. Shafer, 2019, The Journal of antimicrobial chemotherapy.

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients : A randomized controlled comparison with zidovudine monotherapy

P. Harrigan, S. Staszewski, M. Johnson, 1996 .

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

P. Harrigan, S. Staszewski, C. Loveday, 1996, JAMA.

Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.

C Stone, P. Harrigan, B. Larder, 2000, The Journal of infectious diseases.

Utilization of a liver allograft from a hepatitis B surface antigen positive donor.

P. Harrigan, C. Scudamore, U. Steinbrecher, 2006, Transplantation.

Connection Domain Mutations N348I and A360V in HIV-1 Reverse Transcriptase Enhance Resistance to 3′-Azido-3′-deoxythymidine through Both RNase H-dependent and -independent Mechanisms

P. Harrigan, B. Wynhoven, G. Beilhartz, 2008, Journal of Biological Chemistry.

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.

P. Harrigan, C. Alexander, J. Montaner, 2002, The New England journal of medicine.

Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness

P. Harrigan, N. Parkin, D. Bangsberg, 2006, AIDS.

Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection.

P. Harrigan, B. Yip, R. Hogg, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy

Evan Wood, P. Harrigan, B. Yip, 2007, AIDS.

Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART

P. Harrigan, B. Yip, R. Hogg, 2006, PLoS medicine.

Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada

P. Harrigan, J. Shoveller, Z. Brumme, 2017, PloS one.

Risk of Viral Failure Declines With Duration of Suppression on Highly Active Antiretroviral Therapy Irrespective of Adherence Level

P. Harrigan, B. Yip, R. Hogg, 2010, Journal of acquired immune deficiency syndromes.

Epidemiology of treatment failure: a focus on recent trends

P. Harrigan, R. Hogg, J. Montaner, 2009, Current opinion in HIV and AIDS.

The Relationship Between Resistance and Adherence in Drug-Naive Individuals Initiating HAART Is Specific to Individual Drug Classes

P. Harrigan, R. Hogg, J. Montaner, 2008, Journal of acquired immune deficiency syndromes.

Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.

P. Harrigan, B. Yip, R. Hogg, 2008, The Journal of infectious diseases.

Why are Baseline HIV RNA Levels 100,000 Copies/mL or Greater Associated With Mortality After the Initiation of Antiretroviral Therapy?

P. Harrigan, B. Yip, R. Hogg, 2005, Journal of acquired immune deficiency syndromes.

Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.

A. Levy, P. Harrigan, B. Yip, 2004, The Journal of infectious diseases.

Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response

P. Harrigan, R. Hogg, J. Montaner, 2003, AIDS.

Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy

P. Harrigan, R. Hogg, J. Montaner, 2002, Antiviral therapy.

P0891 : Resistance analysis of virologic failures in Hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir +/− ribavirin: The C-worthy study

P. Harrigan, A. Howe, C. Brumme, 2015 .

Comparison of Costs of Strategies for Measuring Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma by Using Amplicor and Ultra Direct Assays

P. Harrigan, R. Hogg, J. Montaner, 1998, Journal of Clinical Microbiology.

“Deep” Sequencing Accuracy and Reproducibility Using Roche/454 Technology for Inferring Co-Receptor Usage in HIV-1

P. Harrigan, D. Knapp, A. Poon, 2014, PloS one.

Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.

P. Harrigan, J. Montaner, J. Min, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration

Lynn Morris, Anne-Mieke Vandamme, Praphan Phanuphak, 2005, PLoS medicine.

HIV therapy, hepatitis C virus infection, antibiotics and obesity, a mitochondria killer mix?

P. Harrigan, J. Montaner, Z. Brumme, 2006, AIDS.

P. Harrigan, B. Yip, R. Hogg, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and l-2′,3′-Dideoxy-3′-Thiacytidine

John W. Mellors, Brendan A. Larder, Stuart Bloor, 1998, Journal of Virology.

Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation.

P. Harrigan, R. Hogg, J. Montaner, 1999, The Journal of infectious diseases.

Early initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral blood.

P. Harrigan, M. Ostrowski, T. Chun, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Post-Marketing Experience with Nevirapine Extended Release (XR) Tablets: Effectiveness and Tolerability in a Population-Based Cohort in British Columbia, Canada

P. Harrigan, B. Yip, R. Hogg, 2015, Antiviral therapy.

Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study

Evan Wood, Kate Shannon, Thomas Kerr, 2010, The Lancet.

Blood mitochondrial DNA mutations in HIV-infected women and their infants exposed to HAART during pregnancy

P. Harrigan, D. Money, E. Maan, 2012, AIDS.

The impact of human genetic variation on HIV disease in the era of HAART.

P. Harrigan, Z. Brumme, 2006, AIDS reviews.

Simplification of Therapeutic Drug Monitoring for Twice-Daily Regimens of Lopinavir/Ritonavir for HIV infection

P. Harrigan, C. Alexander, J. Montaner, 2004, Therapeutic drug monitoring.

HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study

P. Harrigan, J. Montaner, M. Harris, 2017, AIDS Research and Therapy.

Reconstructing the Dynamics of HIV Evolution within Hosts from Serial Deep Sequence Data

Art F. Y. Poon, P. Richard Harrigan, Hanneke Schuitemaker, 2012, PLoS Comput. Biol..

Dates of HIV infection can be estimated for seroprevalent patients by coalescent analysis of serial next-generation sequencing data

Art F Y Poon, Bluma Brenner, David J H F Knapp, 2011, AIDS.

Prospective longitudinal analysis of viral load and surrogate markers in relation to clinical progression in HIV type 1-infected persons.

P. Harrigan, B. Larder, S. Bruisten, 1997, AIDS research and human retroviruses.

Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis.

Curtis Cooper, Bob Hogg, P. Harrigan, 2012, The Journal of infectious diseases.

In vitro functional assessment of natural HIV-1 group M Vpu sequences using a universal priming approach.

Jeffrey N. Martin, P. Harrigan, S. Ávila-Ríos, 2017, Journal of virological methods.

Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir.

R. Shafer, P. Harrigan, S. Holmes, 2022, Antiviral research.

Estimating the Respective Contributions of Human and Viral Genetic Variation to HIV Control

Paul J. McLaren, Jacques Fellay, Amalio Telenti, 2015, bioRxiv.

Adaptation of HIV-1 to human leukocyte antigen class I

David Heckerman, John Frater, Rodney Phillips, 2009, Nature.

Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1

David Heckerman, Tanmoy Bhattacharya, Christian Brander, 2007, PLoS pathogens.

Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users.

P. Harrigan, C. Alexander, J. Montaner, 1999, AIDS.

Quality Control of Next-Generation Sequencing-Based HIV-1 Drug Resistance Data in Clinical Laboratory Information Systems Framework

Rupert Capina, Katherine Li, Levon Kearney, 2020, Viruses.

Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda

M. Carrington, Jeffrey N. Martin, P. Harrigan, 2021, AIDS.

Extensive host immune adaptation in a concentrated North American HIV epidemic

P. Harrigan, J. Joy, S. Sanche, 2018, AIDS.

Novel HLA class I associations with HIV-1 control in a unique genetically admixed population

P. Harrigan, S. Ávila-Ríos, G. Reyes-Terán, 2018, Scientific Reports.

HIV Drug Resistance Testing by High-Multiplex “Wide” Sequencing on the MiSeq Instrument

Jeffrey N. Martin, P. Harrigan, A. R. Mocello, 2015, Antimicrobial Agents and Chemotherapy.

The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study.

Richard H. Liang, Rosemary M. McCloskey, J. Ward, 2016, The Lancet. Infectious diseases.

Genotypic and Mechanistic Characterization of Subtype-Specific HIV Adaptation to Host Cellular Immunity

M. Carrington, Jeffrey N. Martin, P. Harrigan, 2018, Journal of Virology.

HLA-Associated Viral Mutations Are Common in Human Immunodeficiency Virus Type 1 Elite Controllers

F. Pereyra, T. Miura, B. Walker, 2009, Journal of Virology.

Phylogenetic Dependency Networks: Inferring Patterns of CTL Escape and Codon Covariation in HIV-1 Gag

David Heckerman, Carl Myers Kadie, Bruce D. Walker, 2008, PLoS Comput. Biol..

Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection

David Heckerman, Christian Brander, Nicole Frahm, 2008, AIDS.

Validation of a Genotype-Independent Hepatitis C Virus Near-Whole Genome Sequencing Assay

P. Harrigan, A. Poon, C. Brumme, 2021, Viruses.

Title Ability of HIV-1 Nef to downregulate CD 4 and HLA class I differs among viral subtypes Permalink

Rosemary M. McCloskey, Jaclyn K. Mann, B. Walker, 2013 .

Sources and Magnitude of Intralaboratory Variability in a Sequence-Based Genotypic Assay for Human Immunodeficiency Virus Type 1 Drug Resistance

P. Harrigan, B. Wynhoven, M. O’Shaughnessy, 2003, Journal of Clinical Microbiology.

HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort

Julio S. G. Montaner, Michael V. O'Shaughnessy, P. Harrigan, 2001, AIDS.

Basis for Early and Preferential Selection of the E138K Mutation in HIV-1 Reverse Transcriptase

P. Harrigan, M. Wainberg, B. Brenner, 2013, Antimicrobial Agents and Chemotherapy.

A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.

P. Harrigan, B. Yip, J. Montaner, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Association between HIV-1 RNA level and CD4 cell count among untreated HIV-infected individuals.

P. Harrigan, B. Yip, R. Hogg, 2009, American journal of public health.

AssociationBetweenHIV-1RNALevelandCD4Cell CountAmongUntreatedHIV-InfectedIndividuals

P. Harrigan, B. Yip, R. Hogg, 2009 .

Increasingly successful highly active antiretroviral therapy delays the emergence of new HLA class I-associated escape mutations in HIV-1.

P. Harrigan, B. Wynhoven, D. Knapp, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates

Tobias Sing, Andrew J. Low, M. Jensen, 2007, AIDS.

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.

Philip L. Tzou, R. Shafer, P. Harrigan, 2019, The Journal of antimicrobial chemotherapy.

Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection

P. Harrigan, J. Montaner, K. Chan, 2003, AIDS.

Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use

Evan Wood, P. Harrigan, B. Yip, 2005, AIDS.

Significance and Clinical Management of Persistent Low-Level Viremia and Very-Low-Level Viremia in HIV-1-Infected Patients

P. Harrigan, Patrick A Ryscavage, B. Taiwo, 2014, Antimicrobial Agents and Chemotherapy.

Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy.

P. Harrigan, J. Montaner, M. Whaley, 1999, AIDS.

One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States

Sally S Bebawy, Richard D Moore, Jennifer S. Lee, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

Jerome H. Kim, J. Ioannidis, D. Katzenstein, 2015, PLoS medicine.

An Evaluation of Phylogenetic Methods for Reconstructing Transmitted HIV Variants using Longitudinal Clonal HIV Sequence Data

Art F. Y. Poon, Zabrina L. Brumme, Richard H. Liang, 2014, Journal of Virology.

Detection of Inferred CCR5- and CXCR4-Using HIV-1 Variants and Evolutionary Intermediates Using Ultra-Deep Pyrosequencing

E. Bunnik, H. Schuitemaker, P. Harrigan, 2011, PLoS pathogens.

Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.

Alexander Thielen, M. Jensen, P. Harrigan, 2011, The Journal of infectious diseases.

The Evolutionary Analysis of Emerging Low Frequency HIV-1 CXCR4 Using Variants through Time—An Ultra-Deep Approach

David L. Robertson, Marilyn Lewis, Andrew Rambaut, 2010, PLoS Comput. Biol..

Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping

Emma R Lee, Mark Howison, Shuntai Zhou, 2020, Viruses.

Automating HIV Drug Resistance Genotyping with RECall, a Freely Accessible Sequence Analysis Tool

Tommy F. Liu, R. Shafer, A. Chu, 2012, Journal of Clinical Microbiology.

Transmission of Drug-Resistant HIV-1 from an Infected Individual to a Caregiver

P. Harrigan, J. Montaner, B. Wynhoven, 2007, Antiviral therapy.

Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda.

Jeffrey N. Martin, P. Harrigan, D. Knapp, 2014, AIDS research and human retroviruses.

Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy

James I Mullins, M. Jensen, J. Mullins, 2004, AIDS.

Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens

P. Harrigan, B. Yip, R. Hogg, 2001, AIDS.

Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

Jerome H. Kim, J. Ioannidis, D. Katzenstein, 2015, PLoS medicine.

Are We Ready for NGS HIV Drug Resistance Testing? The Second “Winnipeg Consensus” Symposium

R. Paredes, P. Harrigan, N. Parkin, 2020, Viruses.

Development and Validation of a Composite Programmatic Assessment Tool for HIV Therapy

P. Harrigan, B. Yip, R. Hogg, 2012, PloS one.

Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries

Curtis Cooper, Marek Smieja, P. Harrigan, 2010, BMC infectious diseases.

Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort

P. Harrigan, B. Yip, R. Hogg, 2016, BMC Infectious Diseases.

The M184 V mutation in HIV‐1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross‐resistance to nucleoside analogue RT inhibitors

P. Harrigan, K. Hertogs, R. Pauwels, 1998, AIDS.

Human Immunodeficiency Virus Viral Load Rebound Near Delivery in Previously Suppressed, Combination Antiretroviral Therapy-Treated Pregnant Women.

P. Harrigan, E. Wagner, D. Money, 2017, Obstetrics and gynecology.

Mitochondrial DNA somatic mutation burden and heteroplasmy are associated with chronological age, smoking, and HIV infection

S. Kalloger, P. Harrigan, Min Li, 2019, Aging cell.

Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients

P. Harrigan, B. Yip, R. Hogg, 2007, AIDS.

Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy.

P. Harrigan, R. Hogg, J. Montaner, 2007, The Journal of infectious diseases.

Relative Replicative Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro

P. Harrigan, B. Larder, S. Bloor, 1998, Journal of Virology.

Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility

P. Harrigan, B. Larder, S. Kemp, 1996, Journal of virology.

Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes

P. Harrigan, R. Hogg, J. Montaner, 2015, AIDS.

Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study

Evan Wood, Kathy Li, Thomas Kerr, 2009, BMJ : British Medical Journal.

Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia.

David W. Williamson, Jeffrey N. Martin, P. Harrigan, 2006, The Journal of infectious diseases.

Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals.

P. Harrigan, R. Hogg, J. Montaner, 2005, The Journal of infectious diseases.

Determining Human Immunodeficiency Virus Coreceptor Use in a Clinical Setting: Degree of Correlation between Two Phenotypic Assays and a Bioinformatic Model

Tobias Sing, Andrew J. Low, Peter K. Cheung, 2006, Journal of Clinical Microbiology.

Screening for HIV Tropism Using Population-based V3 Genotypic Analysis: A Retrospective Outcome Analysis Using Stored Plasma Screening Samples from MOTIVATE-1

M. Jensen, P. Harrigan, H. Valdez, 2009 .

Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data

S. Hammer, B. Gazzard, L. Bacheler, 2008, Journal of acquired immune deficiency syndromes.

Human Immunodeficiency Virus Type 1 Protease Cleavage Site Mutations Associated with Protease Inhibitor Cross-Resistance Selected by Indinavir, Ritonavir, and/or Saquinavir

P. Harrigan, Z. Brumme, H. Côté, 2001, Journal of Virology.

Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.

P. Harrigan, D. Knox, P. Anderson, 2017, The New England journal of medicine.

HIV antiviral drug resistance: patient comprehension

Kimberly A. Fernandes, P. Harrigan, R. Hogg, 2010, AIDS care.

Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach

P. Harrigan, J. Montaner, J. Raghwani, 2018, Journal of viral hepatitis.

Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.

P. Harrigan, C. Alexander, J. Montaner, 2000, The Journal of infectious diseases.

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.

J W Mulder, R. Schooley, P. Harrigan, 1996, The Journal of infectious diseases.

Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification

P. Harrigan, J. Montaner, Lu Wang, 2017, PloS one.

Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada.

P. Harrigan, J. Montaner, B. Marshall, 2015, Drug and alcohol dependence.

Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

Dao Sen Wang, M. Poljak, F. Ceccherini‐Silberstein, 2022, JHEP reports : innovation in hepatology.

Prevalence and Response to Antiretroviral Therapy of Non-B Subtypes of HIV in Antiretroviral-Naive Individuals in British Columbia

P. Harrigan, C. Alexander, J. Montaner, 2002, Antiviral therapy.

Predictive Value of HIV-1 Protease Genotype and Virtual Phenotype on the Virological Response to Lopinavir/Ritonavir-Containing Salvage Regimens

P. Harrigan, R. Hogg, J. Montaner, 2004, Antiviral therapy.

Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Rates of new infections in British Columbia continue to decline at a faster rate than in other Canadian regions

P. Harrigan, E. Wood, T. Kerr, 2013, HIV medicine.

Prevalence of Human Immunodeficiency Virus-1 Integrase Strand Transfer Inhibitor Resistance in British Columbia, Canada Between 2009 and 2016: A Longitudinal Analysis

P. Harrigan, B. Yip, J. Joy, 2019, Open forum infectious diseases.

OP-JANM190417 1..13

Philip L. Tzou, R. Shafer, P. Harrigan, 2019 .

Emergent drug resistance with integrase strand transfer inhibitor-based regimens

P. Harrigan, B. Yip, J. Montaner, 2017, AIDS.

Replication Fitness of Multiple Nonnucleoside Reverse Transcriptase-Resistant HIV-1 Variants in the Presence of Etravirine Measured by 454 Deep Sequencing

P. Harrigan, A. Poon, K. Huber, 2013, Journal of Virology.

Trends in Plasma HIV-RNA Suppression and Antiretroviral Resistance in British Columbia, 1997–2010

P. Harrigan, R. Hogg, J. Montaner, 2014, Journal of acquired immune deficiency syndromes.

Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States

Sally S Bebawy, Richard D Moore, K. Anastos, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Structural Descriptors of gp120 V3 Loop for the Prediction of HIV-1 Coreceptor Usage

Thomas Lengauer, Oliver Sander, Ingolf Sommer, 2007, PLoS Comput. Biol..

Prolonged and Substantial Discordance in Prevalence of Raltegravir-Resistant HIV-1 in Plasma versus PBMC Samples Revealed by 454 “Deep” Sequencing

Jeffrey N. Martin, P. Harrigan, M. Wainberg, 2012, PLoS ONE.

CD4+ T-Cell Gain With Nonnucleoside or Protease Inhibitors: Convenience May Not Always Be The Most Convenient:Reply

P. Harrigan, B. Yip, R. Hogg, 2004 .

Extent of Cross-Resistance between Agents Used To Treat Human Immunodeficiency Virus Type 1 Infection in Clinically Derived Isolates

Brendan A. Larder, P. Harrigan, B. Larder, 2002, Antimicrobial Agents and Chemotherapy.

Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches

Jeffrey N. Martin, P. Harrigan, M. Siedner, 2017, AIDS.

Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.

P. Harrigan, A. Poon, A. Wensing, 2013, The Journal of antimicrobial chemotherapy.

UvA-DARE ( Digital Academic Repository ) Detection of inferred CCR 5-and CXCR 4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing

E. Bunnik, H. Schuitemaker, P. Harrigan, 2011 .

Improved prediction of HIV‐1 coreceptor usage with sequence information from the second hypervariable loop of gp120.

Thomas Lengauer, Rolf Kaiser, Alexander Thielen, 2010, The Journal of infectious diseases.

On-demand, hospital-based, severe acute respiratory coronavirus virus 2 (SARS-CoV-2) genomic epidemiology to support nosocomial outbreak investigations: A prospective molecular epidemiology study

P. Harrigan, D. Kaufmann, S. Grandjean Lapierre, 2023, Antimicrobial Stewardship & Healthcare Epidemiology.

Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply.

P. Harrigan, B. Yip, R. Hogg, 2008, AIDS (London).

Longitudinal trends of HIV drug resistance in a large Canadian cohort, 1996-2016.

P. Harrigan, J. Shoveller, C. Brumme, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure.

P. Harrigan, J. Montaner, L. C. Swenson, 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Epidemiology of antiretroviral multiclass resistance.

P. Harrigan, B. Yip, R. Hogg, 2010, American journal of epidemiology.

Are untimed antiretroviral drug levels useful predictors of adherence behavior?

P. Harrigan, C. Alexander, D. Bangsberg, 2003, AIDS.

Patterns of Transmitted Drug Resistance and Virological Response to First-line Antiretroviral Treatment Among Human Immunodeficiency Virus–Infected People Who Use Illicit Drugs in a Canadian Setting

P. Harrigan, J. Montaner, T. Kerr, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Nucleic acid differences between HIV-1 non-B and B reverse transcriptase and protease sequences at drug resistance positions

Soriano, D. Katzenstein, R. Shafer, 2003 .

The use of virtual inhibitory quotient (VIQ) in antiretroviral (ART) experienced patients taking amprenavir/lopinavir combinations

P. Harrigan, M. Loutfy, S. Walmsley, 2002 .

Nano‐RECall provides an integrated pipeline for HIV‐1 drug resistance testing from Oxford Nanopore sequence data

P. Harrigan, U. Parikh, C. Woods, 2023, Tropical medicine & international health : TM & IH.

Dolutegravir with boosted darunavir treatment simplification for the transmitted HIV thymidine analog resistance in Manitoba, Canada

S. Chan, P. Harrigan, M. Becker, 2018, International journal of STD & AIDS.

Risk of Breast Cancer With CXCR4-Using HIV Defined by V3 Loop Sequencing

J. Goedert, K. Anastos, M. Young, 2015, Journal of acquired immune deficiency syndromes.

HIV-1 drug resistance surveillance using dried whole blood spots

Paul Sandstrom, P. Harrigan, L. Soto-Ramírez, 2007, Antiviral therapy.

Performance of a World Health Organization first‐line regimen (stavudine/lamivudine/nevirapine) in antiretroviral‐naïve individuals in a Western setting

P. Harrigan, J. Montaner, B. Yip, 2007, HIV medicine.

“Dynamic Range” of Inferred Phenotypic HIV Drug Resistance Values in Clinical Practice

P. Harrigan, R. Hogg, J. Montaner, 2011, PloS one.

Predictors of Virological Response in HIV-Infected Patients to Salvage Antiretroviral Therapy that Includes Nelfinavir

M. Zhang, P. Harrigan, A. Humar, 2001, Antiviral therapy.

Theoretical and experimental assessment of degenerate primer tagging in ultra-deep applications of next-generation sequencing

Jeffrey B. Joy, Richard H. Liang, Rosemary M. McCloskey, 2014, Nucleic acids research.

Narrowing down the causes of failure of tenofovir (only) for preexposure prophylaxis.

P. Harrigan, H. Lapointe, 2019, AIDS.

Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.

P. Harrigan, R. Hogg, J. Montaner, 2005, Antiviral therapy.

Reliable Genotypic Tropism Tests for the Major HIV-1 Subtypes

P. Harrigan, M. Churchill, P. Gorry, 2015, Scientific Reports.

2004: which HIV-1 drug resistance mutations are common in clinical practice?

P. Harrigan, B. Wynhoven, P. Cheung, 2004, AIDS reviews.

Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy.

P. Harrigan, A. Humar, S. Walmsley, 2001, AIDS.

Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors are subtype dependent

Lynn Morris, Anne-Mieke Vandamme, Praphan Phanuphak, 2004 .

"Test-and-treat" strategy for control of HIV and AIDS can lead to a decrease, not an increase, of multidrug-resistant viruses.

P. Harrigan, J. Montaner, C. Brumme, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In Vitro Selection of Clinically Relevant Bevirimat Resistance Mutations Revealed by “Deep” Sequencing of Serially Passaged, Quasispecies-Containing Recombinant HIV-1

P. Harrigan, D. Knapp, A. Poon, 2010, Journal of Clinical Microbiology.

Calibration and accuracy of the geno2pheno co-receptor algorithm for predicting HIV tropism for single and triplicate measurements of V3 genotype

P. Harrigan, D. Knapp, L. Swenson, 2010, Journal of the International AIDS Society.

Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa

P. Harrigan, J. Mellors, K. McCormick, 2020, Antimicrobial Agents and Chemotherapy.

Earlier initiation of highly active antiretroviral therapy does not protect against the deleterious effects of non-adherence

P. Harrigan, B. Yip, R. Hogg, 2004, AIDS.

Efficacy and safety of “unboosting” atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF

P. Harrigan, M. Harris, M. Hull, 2017, HIV clinical trials.

HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy.

P. Harrigan, J. Montaner, A. Badley, 2006, AIDS research and human retroviruses.

Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study.

Richard D Moore, Jennifer S. Lee, J. Margolick, 2019, The lancet. HIV.

AIDS Care : Psychological and Socio-medical Aspects of AIDS / HIV

Kimberly A. Fernandes, P. Harrigan, R. Hogg, 2010 .

Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.

P. Harrigan, B. Yip, R. Hogg, 2005, The Journal of infectious diseases.

Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring.

D. Moodley, P. Harrigan, R. V. Leeuwen, 1998, The Journal of infectious diseases.

HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach.

P. Harrigan, J. Montaner, B. Wynhoven, 2005, The Journal of infectious diseases.

Using baseline CD4 cell count and plasma HIV RNA to guide the initiation of highly active antiretroviral therapy.

P. Harrigan, B. Yip, R. Hogg, 2004, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

Meta-analysis of Two Randomized Controlled Trials Comparing Combined Zidovudine and Didanosine Therapy With Combined Zidovudine, Didanosine, and Nevirapine Therapy in Patients With HIV

P. Harrigan, J. Montaner, J. Raboud, 1999 .

Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005‐2013

Jeffrey N. Martin, P. Harrigan, M. Siedner, 2018, AIDS patient care and STDs.

Viral load testing in a resource-limited setting: quality control is critical

P. Harrigan, P. Cros, P Richard Harrigan, 2011, Journal of the International AIDS Society.

Development of a novel codon-specific polymerase chain reaction for the detection of CXCR4-utilizing HIV type 1 subtype B.

P. Harrigan, R. Coombs, L. Frenkel, 2013, AIDS research and human retroviruses.

Optimization of Clinical Cutoffs for Determining HIV Co-Receptor Use by Population and “Deep” Sequencing Methods

P. Harrigan, 2009 .

The T cell receptor vβ repertoire shows little change during treatment interruption-related viral rebound in chronic HIV infection

P. Harrigan, J. Montaner, M. Grant, 2002 .

Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing

W. Heneine, P. Harrigan, C. Gray, 2011, PloS one.

HIV drug resistance over the long haul.

P. Harrigan, 2010, Clinical Infectious Diseases.

"Test-and-treat" strategy for control of HIV and AIDS can lead to a decrease, not an increase, of multidrug-resistant viruses.

P. Harrigan, J. Montaner, C. Brumme, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis

J. Sterne, A. Mocroft, P. Harrigan, 2016, AIDS.

Uncommon Pathways of Immune Escape Attenuate HIV-1 Integrase Replication Capacity

D. Heckerman, E. Rosenberg, H. Jessen, 2012, Journal of Virology.

Early Selection in Gag by Protective HLA Alleles Contributes to Reduced HIV-1 Replication Capacity That May Be Largely Compensated for in Chronic Infection

Todd M. Allen, D. Heckerman, E. Rosenberg, 2010, Journal of Virology.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

R. C. Rose, Todd M. Allen, David S. Rubin, 2010, Science.

Prediction of response to antiretroviral therapy by human experts and by the EuResist data‐driven expert system (the EVE study)

Thomas Lengauer, A. Wensing, R. Kaiser, 2010, HIV medicine.

Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide.

P. Harrigan, J. Montaner, D. Rouleau, 2007, Antiviral research.

Systematic determination of in vitro phenotypic resistance to HIV-1 integrase strand transfer inhibitors from clinical samples

P. Harrigan, M. Robbins, C. Brumme, 2019, bioRxiv.